Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M1,757Revenue $M71.0Net Margin (%)46.0Altman Z-Score3.2
Enterprise Value $M1,775EPS $1.6Operating Margin %29.4Piotroski F-Score7
P/E(ttm)57.2Beneish M-Score-3.3Pre-tax Margin (%)42.4Higher ROA y-yY
Price/Book25.410-y EBITDA Growth Rate %--Quick Ratio10.9Cash flow > EarningsN
Price/Sales26.25-y EBITDA Growth Rate %--Current Ratio11.0Lower Leverage y-yN
Price/Free Cash Flow136y-y EBITDA Growth Rate %28.7ROA % (ttm)13.6Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)68.3Less Shares Outstanding y-yY
Payout Ratio %--Shares Outstanding M19.9ROIC % (ttm)34.5Gross Margin Increase y-yY

Gurus Latest Trades with LGND

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
LGNDKen Fisher 2015-06-30 Reduce$75.67 - $100.9
($87.3)
$ 88.481%Reduce 1.59%80,608
LGNDJoel Greenblatt 2015-03-31 Sold Out -0.0016%$51.54 - $77.11
($61.42)
$ 88.4844%Sold Out0
LGNDJoel Greenblatt 2014-12-31 Reduce-0.26%$42.36 - $57.96
($52.25)
$ 88.4869%Reduce 99.32%3,766
LGNDKen Fisher 2014-12-31 Add0.01%$42.36 - $57.96
($52.23)
$ 88.4869%Add 132.31%81,908
LGNDJoel Greenblatt 2014-09-30 Add0.23%$46.99 - $64.52
($53.04)
$ 88.4867%Add 894.83%552,053
LGNDJoel Greenblatt 2014-06-30 Buy 0.04%$59.74 - $70.19
($65.09)
$ 88.4836%New holding55,492
LGNDKen Fisher 2014-06-30 Buy $59.74 - $70.19
($65.09)
$ 88.4836%New holding36,908
LGNDJoel Greenblatt 2014-03-31 Sold Out -0.02%$51.52 - $79.58
($66.37)
$ 88.4833%Sold Out0
LGNDJoel Greenblatt 2013-12-31 Add0.01%$44.86 - $57.95
($52.33)
$ 88.4869%Add 124.95%13,803
LGNDJoel Greenblatt 2013-09-30 Buy 0.01%$38.69 - $49.66
($45.21)
$ 88.4896%New holding6,136
LGNDGeorge Soros 2011-09-30 Sold Out -0.0017%$10.89 - $15.95
($13.18)
$ 88.48571%Sold Out0
LGNDGeorge Soros 2011-06-30 Buy $9.56 - $12.02
($10.55)
$ 88.48739%New holding10,000
LGNDGeorge Soros 2009-12-31 Sold Out $9.96 - $14.16
($12.14)
$ 88.48629%Sold Out0
LGNDGeorge Soros 2009-09-30 Buy $13.74 - $18.9
($16.16)
$ 88.48448%New holding4,483
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

LGND is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


LGND: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
KNOTT DAVID MDirector 2015-08-17Sell4,000$95.98-7.81view
KNOTT DAVID MDirector 2015-08-13Sell49,800$96.26-8.08view
KNOTT DAVID MDirector 2015-08-07Sell200$99.02-10.64view
HIGGINS JOHN LCEO 2015-08-06Sell4,666$110.79-20.14view
Berkman Charles SVP, Gen. Counsel & Secretary 2015-07-10Sell14,067$99.14-10.75view
FOEHR MATTHEW WPresident and COO 2015-06-26Sell12,500$100.97-12.37view
FOEHR MATTHEW WPresident and COO 2015-06-22Sell23,046$96.45-8.26view
Herman Melanie JInterim CFO 2015-06-10Sell4,125$93.5-5.37view
HIGGINS JOHN LCEO 2015-06-09Sell10,000$92.88-4.74view
Aryeh JasonDirector 2015-06-04Sell1,640$92.68-4.53view

Quarterly/Annual Reports about LGND:

News about LGND:

Articles On GuruFocus.com
Dan Loeb Sees Opportunity in Latest Activist Target Baxter International Aug 06 2015 
Dan Loeb Sees Opportunity in Latest Activist Target Baxter International Aug 06 2015 
dick Feb 13 2015 
Ligand Pharmaceuticals - Severe competitive threat to key royalty program and “going concern” ri Jun 19 2014 
5 Hot Stocks to Consider Now Mar 30 2012 
Ligand Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 05 2010 
Ligand Pharmaceuticals Inc. Reports Operating Results (10-Q) May 05 2010 
Ligand Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 09 2009 
Ligand to Acquire Neurogen for Stock and Contingent Value Rights Aug 24 2009 
Ligand Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 04 2009 

More From Other Websites
Revolade® Receives EU Approval as First-in-Class Therapy for Patients with Severe Aplastic Anemia Sep 02 2015
Revolade® Receives EU Approval as First-in-Class Therapy for Patients with Severe Aplastic Anemia Sep 02 2015
Spectrum Pharmaceuticals Announces Publication of Pivotal EVOMELA™ (melphalan hydrochloride) for... Sep 02 2015
Novartis' (NVS) Promacta Label Further Expanded in U.S. Aug 26 2015
Ligand Pharmaceuticals, Inc. Earnings Q2, 2015 Aug 26 2015
FDA Expands Use of Promacta® to Include Treatment of Children Ages 1 and Older with Chronic Immune... Aug 24 2015
FDA Expands Use of Promacta® to Include Treatment of Children Ages 1 and Older with Chronic Immune... Aug 24 2015
LIGAND PHARMACEUTICALS INC Financials Aug 12 2015
10-Q for Ligand Pharmaceuticals, Inc. Aug 08 2015
Dan Loeb Sees Opportunity in Latest Activist Target Baxter International Aug 06 2015
LIGAND PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers Aug 06 2015
SurModics (SRDX) Beats on Q3 Earnings, Improves Outlook - Analyst Blog Aug 06 2015
Poseida Therapeutics, Inc., Expands Board of Directors Aug 05 2015
Ligand Pharmaceuticals Beats on Q2 Earnings, Affirms View - Analyst Blog Aug 05 2015
LIGAND PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report Aug 05 2015
Ligand Reports Second Quarter 2015 Financial Results Aug 05 2015
Matthew Korenberg to Join Ligand Pharmaceuticals as Chief Financial Officer Aug 05 2015
Edited Transcript of LGND earnings conference call or presentation 4-Aug-15 8:30pm GMT Aug 04 2015
Ligand posts 2Q profit Aug 04 2015
Ligand posts 2Q profit Aug 04 2015

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK